Kambarov Y

Johnson & Johnson , ,

8 papers · ORCID

ArticleKetamine

ECHO: Results from a Non-Interventional Cohort Study of Esketamine Nasal Spray in Treatment Resistant Depression

Rosso G, Constant E, De Filippis S +12

Europe PMC2026
ArticleKetamine

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Reif A, Anıl Yağcıoğlu AE, Bitter I +11

Europe PMC2026
ArticleKetamine

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release.

Reif A, Baune BT, Buyze J +8

Europe PMC2025
ArticleKetamine

Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant Depression

Vieta E, Ahmed N, Arango C +11

Europe PMC2025
ArticleKetamine

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

Vieta E, Ahmed N, Arango C +11

Europe PMC2025
ArticleKetamine

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Reif A, Anıl Yağcıoğlu A, Luts A +10

Europe PMC2023